A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

UCI-15-69
NCT02421939
Cancer - Leukemia, other
Deepa Jeyakumar
Open
Treatment
ASP2215, Azacitidine, Cytarabine, Etopophos, Etoposide, Fludarabine, G-CSF (Granulocyte colony-stimulating factor 300µg/m2), Idarubicin, Mitoxantrone
III
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.